Drug
Ak127 Q3w Infusion
Ak127 Q3w Infusion: highest development phase Phase 1, developed by Akeso. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Akeso
Trials
| Drug | Phase | Indication |
|---|---|---|
| AK127 Q3W IV infusion ,AK104 10mg/kg Q3W IV infusion NCT05868876 | Phase 1 | Advanced Malignant Tumors |
Latest
No recent events.
Follow Ak127 Q3w Infusion on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.